Logo

Biosearch Gets $3.4M Contract from FDA

Oct 05, 2009

NEW YORK (GenomeWeb News) – Biosearch Technologies today announced that the US Food and Drug Administration has awarded the firm a $3.4 million contract to develop rapid, multiplexed fluorescent assays for identifying bioterror and food safety pathogens.

The Novato, Calif.-based firm said that it will work with Pejman Naraghi-Arani at Lawrence Livermore National Laboratories and Luminex to develop rapid, highly specific assays for agents listed as "Select Agents" by the Centers for Disease Control and Prevention and the US Department of Agriculture. The assays will run on the Luminex xMAP platform.

Initial target analytes for the project include Bacillus anthracis, Yersinia pestis, and Francisells tularensis.

Filed under

Diagnostics
Microarrays & Multiplexing
FDA
translational research
xMAP
Luminex
LGC
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.